Compare Amgen, Inc. (AMGN) vs Norwegian Cruise Line Holdings Ltd (NCLH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Norwegian Cruise Line Holdings Ltd — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Norwegian Cruise Line Holdings Ltd trades at $19.52 (market cap $9.00B). The key difference: Amgen, Inc. is far larger — about 21.8× Norwegian Cruise Line Holdings Ltd's market cap, and Amgen, Inc. pays a 2.77% dividend while Norwegian Cruise Line Holdings Ltd pays none. Which is the better fit depends on your goals.
| AMGN | NCLH | |
|---|---|---|
Market Cap | $196.12B | $9.00B |
Sector | Health | Consumer Cyclical |
52-Week High | $388.16 | $26.94 |
52-Week Low | $271.18 | $14.79 |
Enterprise Value | $241.41B | $23.97B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Norwegian Cruise Line Holdings (NCLH) trades at $19.61, down 0.76% on the day, with technical indicators showing a neutral to bearish bias amid recent volatility. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.23 surpassing expectations of $0.15, while revenue reached $9.83 billion in 2025. Analyst sentiment remains largely positive with a consensus price target of $22.06, though high debt levels and macroeconomic sensitivities present ongoing risks.
NCLH offers potential upside based on earnings momentum and favorable valuation multiples, but investors face headwinds from elevated leverage and industry-specific volatility. The stock's near-term direction hinges on Q2 2026 earnings delivery and sustained travel demand amid fluctuating fuel costs and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Norwegian Cruise Line Holdings Ltd
Norwegian Cruise Line is the world's third-largest cruise company by berths (at more than 62,000), operating 29 ships across three brands (Norwegian, Oceania, and Regent Seven Seas), offering both freestyle and luxury cruising. The company has redeployed its entire fleet as of May 2022. With eight passenger vessels on order among its brands through 2027 (representing 20,000 incremental berths), Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sailed to around 500 global destinations before the pandemic.
Read more on NCLH →
